Morgan Stanley Reiterates Equal-Weight on Pharvaris, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharvaris (NASDAQ:PHVS) and maintained a $10 price target.
June 20, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharvaris and maintained a $10 price target.
The news of Morgan Stanley reiterating an Equal-Weight rating on Pharvaris and maintaining a $10 price target is directly related to PHVS. However, since the rating and price target remain unchanged, the short-term impact on the stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100